Genetic and environmental factors influencing the occurrence of melanoma in the adult population between 30 and 60 years of age
DOI:
https://doi.org/10.35381/s.v.v8i1.3809Keywords:
Melanoma, melanoma, experimental, melanoma amelanotic, (Source: DeCS)Abstract
Objective: to analyze the genetic and environmental factors that influence the appearance of melanoma in the adult population between 30 and 60 years of age. Method: Descriptive documentary. Conclusion: The genetic component shows in detail that most of the young male population suffers from this pathology as a product of the CDKN2A gene mutation, which causes a high rate in the appearance of melanoma, however, despite its high mortality, timely diagnosis and treatment have given the population a satisfactory life prognosis in comparison with patients who do not have access to care services in a timely and early manner. To date, melanoma is a potentially fatal form of skin cancer, accounting for the highest percentage of all skin cancer deaths.
Downloads
References
Teixido C, Castillo P, Martinez-Vila C, Arance A, Alos L. Molecular Markers and Targets in Melanoma. Cells. 2021;10(9):2320. https://doi.org/10.3390/cells10092320
Bobos M. Histopathologic classification and prognostic factors of melanoma: a 2021 update. Ital J Dermatol Venerol. 2021;156(3):300-321. https://doi.org/10.23736/S2784-8671.21.06958-3
Dzwierzynski WW. Melanoma Risk Factors and Prevention. Clin Plast Surg. 2021;48(4):543-550. https://doi.org/10.1016/j.cps.2021.05.001
Ahmed B, Qadir MI, Ghafoor S. Malignant Melanoma: Skin Cancer-Diagnosis, Prevention, and Treatment. Crit Rev Eukaryot Gene Expr. 2020;30(4):291-297. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2020028454
Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet. 2023;402(10400):485-502. https://doi.org/10.1016/S0140-6736(23)00821-8
Mobuchon L, Derrien AC, Houy A, et al. Different Pigmentation Risk Loci for High-Risk Monosomy 3 and Low-Risk Disomy 3 Uveal Melanomas. J Natl Cancer Inst. 2022;114(2):302-309. https://doi.org/10.1093/jnci/djab167
Li C, Liu J, Jiang L, et al. The value of melanoma inhibitory activity and LDH with melanoma patients in a Chinese population. Medicine (Baltimore). 2021;100(8):e24840. https://doi.org/10.1097/MD.0000000000024840
Shen EC, Srinivasan S, Passero LE, et al. Barriers and Facilitators for Population Genetic Screening in Healthy Populations: A Systematic Review. Front Genet. 2022;13:865384. https://doi.org/10.3389/fgene.2022.865384
Wang X, Deng X, Shu Z, Wu J. Diagnosis of primary biliary melanoma with distinct imaging features: a case report and literature review. J Int Med Res. 2023;51(3):3000605231164005. https://doi.org/10.1177/03000605231164005
Patel VR, Roberson ML, Pignone MP, Adamson AS. Risk of Mortality After a Diagnosis of Melanoma In Situ. JAMA Dermatol. 2023;159(7):703-710. https://doi.org/10.1001/jamadermatol.2023.1494
Mou H, Tan Q. Surgical Research Progress of Sentinel Lymph Node Biopsy in Melanoma. J Invest Surg. 2023;36(1):2225087. https://doi.org/10.1080/08941939.2023.2225087
Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. Epidemiology of Melanoma. Med Sci (Basel). 2021;9(4):63. https://doi.org/10.3390/medsci9040063
Ghemrawi M, Tejero NF, Duncan G, McCord B. Pyrosequencing: Current forensic methodology and future applications-a review. Electrophoresis. 2023;44(1-2):298-312. https://doi.org/10.1002/elps.202200177
Pereira I, Monteiro C, Pereira-Silva M, et al. Nanodelivery systems for cutaneous melanoma treatment. Eur J Pharm Biopharm. 2023;184:214-247. https://doi.org/10.1016/j.ejpb.2023.02.002
Gorry C, McCullagh L, O'Donnell H, et al. Neoadjuvant treatment for stage III and IV cutaneous melanoma. Cochrane Database Syst Rev. 2023;1(1):CD012974. https://doi.org/10.1002/14651858.CD012974.pub2
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Lorena Doménica Ortiz-Rivadeneira, Micaela Judith Lliguay-Guanga, Juan Alberto Viteri-Rodríguez
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
OAI-PMH: https://fundacionkoinonia.com.ve/ojs/index.php/saludyvida/oai.
